http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2375350-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c61eaa51339add987e345632cdeb04f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate | 2004-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12c68ff27cc36deb453d939225fb9acf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb1cbf33e13d9107236bef02d13d98e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07e1f11183e310392831bd9324cdfc32 |
| publicationDate | 2009-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2375350-C2 |
| titleOfInvention | Nitrogen-containing heteroaryl derivatives |
| abstract | FIELD: medicine. n SUBSTANCE: in new compounds of formula (I): R 1 is specified from the group including -OR 7 and -NR 8 R 9 ; where R 7 means hydrogen; R 8 and R 9 are independently chosen from the group including hydrogen, aryl, substituted aryl containing one to three substitutes, preferentially one to two substitutes independently chosen from the group including alkenyl, substituted alkenyl containing one to three, preferentially one to two substitutes independently chosen from the group including carboxyl and carboxyl esters; R 2 and R 12 are independently chosen from the group including hydrogen, alkyl and alkyl substituted with 5-hydroxy-indolyl group; or R 2 and R 12 together with carbon atom whereto attached, form cycloalkyl group; R 3 means hydrogen; each R 4 independently means halogen; Q means oxygen; X means oxygen; R 5 means alkylene; R 6 is specified from the group consisting of substituted aryl containing one to three, preferentially one to two substitutes independently chosen from group consisting of acylamino, aryl, substituted aryl, containing one to three, preferentially from one to two substitutes chosen from halogen; and n is equal 0 to 3; or to its pharmaceutically acceptable salts. Besides the invention concerns a pharmaceutical composition, to the method of treatment or prevention of virus infections in mammals. n EFFECT: production of the new biologically active compound active with respect to treatment of virus infections in mammals, partially mediated with a member of flaviviridae virus family. n 12 cl, 5 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2558328-C2 |
| priorityDate | 2003-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 293.